Intranasal pirodavir (R77,975) treatment of rhinovirus colds.

A randomized, double-blind, placebo-controlled trial assessed the therapeutic efficacy of intranasal pirodavir in naturally occurring rhinovirus colds. Adults with symptoms of < or = 2 days' duration were randomly assigned to intranasal sprays of pirodavir (2 mg per treatment) or placebo six times d...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrob Agents Chemother
Hlavní autoři:	Hayden, F G, Hipskind, G J, Woerner, D H, Eisen, G F, Janssens, M, Janssen, P A, Andries, K
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 1995
Témata:	Research Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162529/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7726484/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.2.290
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!